Personalized medicine

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 6, 2002, Pages 548-558

  Jain, Kewal K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

Genetic screening; Genotyping; Individualized treatment; Integrated healthcare; Molecular diagnostics; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Pharmacoproteomics; Single nucleotide polymorphisms

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRIC OXIDE DONOR; PRAVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; BIOINFORMATICS; DIAGNOSTIC TEST; DNA MICROARRAY; DRUG INFORMATION; DRUG METABOLISM; DRUG RESEARCH; GENE EXPRESSION PROFILING; GENETIC TOXICOLOGY; GENOTYPE; HAPLOTYPE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INDIVIDUALIZATION; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICAL TECHNOLOGY; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOGENOMICS; PRESCRIPTION; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL ASPECT;

ANIMALS; DRUG THERAPY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PERSONAL HEALTH SERVICES; PHARMACOGENETICS;

EID: 0036924183     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Jain KK: Personalized Medicine. Decision Resources Inc, Waltham, MA, USA (1998).
2. Jain KK: Personalized Medicine. Informa Pharmaceutical Publications, London, UK (2001).
3. Jain KK: Personalized Medicine. Jain PharmaBiotech Publications, Basel, Switzerland (2003).
4. Kalow W, Meyer U, Tyndale RF (Eds): Pharmacogenomics. Marcel Dekker, New York, NY, USA (2001).
5. Ginsburg GS, McCarthy JJ: Personalized medicine: Revolutionizing drug discovery and patient care. Trends Biotechnol (2001) 19:491-496.
6. Issa AM: Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov (2002) 1:300-308.
7. Jain KK: From molecular diagnostics to personalized medicine. The IBC Workshop, London, UK, 1st May, 2002. Exp Rev Mol Diagn (2002) 2:299-301
8. Lindpaintner K: The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat Rev Drug Discov (2002) 1:463-469.
9. Brookes AJ: The essence of SNPs. Gene (1999)234:177-186.
10. Collins FS, Brooks LD, Chakravarti A: A DNA polymorphism discovery resource for research on human genetic variation. Genome Res (1998) 8:1229-1231.
11. Judson R, Stephens JC, Windemuth A: The predictive power of haplotypes in clinical response. Pharmacogenomics (2000) 1:15-26.
12. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, Jiang R, Messer CJ, Chew A, Han JH, Duan J et al: Haplotype variation and linkage disequilibrium in 313 human genes. Science (2001) 293:489-493.
13. Bader JS: The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics (2001) 2:11-24.
14. Athanasiou MC, Malhotra AK, Xu C, Stephens JC: Discovery and utilization of haplotypes for pharmacogenetic studies of psychotropic drug response. Psychiatr Genet (2002) 12:89-96.
15. Jain KK: Biochips and Microarrays. Informa Pharmaceutical Publications, London, UK (2000).
16. Kalow W: Perspectives in pharmacogenetics. Arch Pathol Lab Med (2001)125:77-80.
17. Dahl ML: Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing? Clin Pharmacokinet (2002) 41:453-470.
18. Meisel C, Roots I, Cascorbi I, Brinkmann U, Brockmoller J: How to manage individualized drug therapy: Application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med (2000) 38:869-876.
19. Exner DV, Dries DL, Domanski W, Cohn JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med (2001) 344:1351-1357.
20. Norton RM: Clinical pharmacogenomics: Applications in pharmaceutical R&D. Drug Discov Today (2001) 6:180-185.
21. Caplan AI, Bruder SP: Mesenchymal stem cells: Building blocks for molecular medicine in the 21st century. Trends Mol Med (2001) 7:259-264.
22. Castle AL, Carver MP, Mendrick DL: Toxicogenomics: A new revolution in drug safety. Drug Disc Today (2002) 7:728-736.
23. Kennedy S: The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis. Biomarkers (2002) 7:269-290.
24. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J (2001) 1:65-70.
25. Rusnak JM, Kisabeth RM, Herbert DP, McNeil DM: Pharmacogenomics: A clinician's primer on emerging technologies for improved patient care. Mayo Clin Proc (2001) 76:299-309.
26. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, Triposkiadis P, Kyriakidis M: Predicting response to chronic antihypertensive treatment with fosinopril: The role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther (2000) 14:427-432.
27. Cacabelos R: Pharmacogenomics in Alzheimer's disease. Mini Rev Med Chem (2002) 2:59-84.
28. Chaix C, Grenier-Sennelier C, Clevenbergh P, Durant J, Schapiro JM, Dellamonica P, Durand-Zaleski I: Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. J Acquir Immune Defic Syndr (2000) 24:227-231.
29. Johnson JA, Evans WE: Molecular diagnostics as a predictive tool: Genetics of drug efficacy and toxicity. Trends Mol Med (2002) 8:300-305.
30. Jain KK: Molecular Diagnostics. Jain PharmaBiotech Publications, Basel, Switzerland (2002).
31. McAlister FA, Straus SE, Guyatt GH, Haynes RB: Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. J Am Med Assoc (2000) 283:2829-2836.
32. Nicewarner-Pena SR, Freeman RG, Reiss BD, He L, Pena DJ, Walton ID, Cromer R, Keating CD, Natan MJ: Submicrometer metallic barcodes. Science (2001) 294:137-141.
33. Augen J: The evolving role of information technology in the drug discovery process. Drug Discov Today (2002) 7:315-323.
34. Tribut O, Lessard Y, Reymann JM, Allain H, Bentue-Ferrer D: Pharmacogenomics. Med Sciences Monitor (2002) 8:RA152-RA163.
35. Vizirianakis IS: Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine. Eur J Pharm Sci (2002) 15:243-250.